checkAd
    Startseite > Aktien > Alvotech > Nachrichten
    Alvotech Aktie
    12,425
     
    EUR
    0,00 %
    0,000 EUR
    Letzter Kurs 20.05.24 Lang & Schwarz
    12,200
     
    EUR
    676 STK
    Geldkurs 20.05.24
    12,650
     
    EUR
    676 STK
    Briefkurs 20.05.24
    ISIN: LU2458332611 · WKN: A3DK8U · Luxemburg

    Neueste Nachrichten

    Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S.
    02:25 Uhr · globenewswire · Alvotech
    Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S.
    02:25 Uhr · globenewswire · Alvotech
    Teva and Alvotech Announce SIMLANDI (adalimumab-ryvk) Injection Now Available in the U.S.
    02:25 Uhr · Business Wire (engl.) · Teva Pharmaceutical Industries
    Alvotech S.A. Annual General Meeting to be held June 7, 2024
    15.05.24 · globenewswire · Alvotech
    Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8: 00 am EDT (12 noon GMT)
    13.05.24 · globenewswire · Alvotech
    Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8: 00 am EDT (12 noon GMT)
    13.05.24 · globenewswire · Alvotech
    Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
    02.05.24 · globenewswire · Alvotech
    Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
    02.05.24 · globenewswire · Alvotech
    U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab)
    30.04.24 · globenewswire · Alvotech
    U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab)
    30.04.24 · globenewswire · Alvotech
    U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab)
    30.04.24 · Business Wire (engl.) · Teva Pharmaceutical Industries
    Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi (golimumab)
    24.04.24 · globenewswire · Alvotech